Page 83 - Merck Sharp News Today

The government announced last year it had advanced purchase agreements for 60,000 doses each of Molnupiravir and Paxlovid, but neither is approved for use here yet.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as... | January 23, 2022

Highlights In an analysis of data from a recent clinical trial, researchers found that removing a race-based adjustment in the estimation of

Natco said with this licence agreement it can manufacture and sell Molnupiravir capsules 200 mg for Indian market, which will be sold under brand name MOLNUNAT for treatment of COVID-19 infection in...

This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name.

Adding pembrolizumab to chemotherapy did not improve outcomes for patients with PD-L1+ advanced gastric/gastroesophageal junction cancer.

Japanese market share in the global pharmaceutical market declined from 12% in 2003 to 7% in 2019. Market size is an important factor in pharmaceutical companies’ decisions to invest in innovation.

Japanese market share in the global pharmaceutical market declined from 12% in 2003 to 7% in 2019. Market size is an important factor in pharmaceutical companies’ decisions to invest in innovation.

Australia's medicines regulator, the Therapeutic Goods Authority (TGA), has provisionally approved two oral medications to treat COVID-19, the ...

The national drug regulator has given the green light to the Novavax vaccine, along with two oral treatments ...